A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Status:
Unknown status
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
This is a Phase I, open-label, multi-center, multi-national, dose escalation, single agent
study to determine the recommended Phase II dose (RP2D) of MCLA-158 in metastatic colorectal
cancer (mCRC). The study will assess the safety, tolerability, PK, PD, immunogenicity, and
anti-tumor activity of MCLA-158 in mCRC and other advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Merus N.V.
Collaborators:
4Clinics Chiltern International Inc. Oncology Therapeutic Development (OTD) Q2 Solutions